At Bryson, we’re committed to our WOW promise, understanding that trust in your broker is built on more than just managing renewals; it’s built on providing the intellectual capital you need to navigate an increasingly complex healthcare world. Today, we’d like to update you on the recent launch of the federal government’s new prescription platform and how it fits into your broader employee benefits strategy. As your strategic partner in all things benefits, we want to ensure you have the facts behind this new platform so you can guide your team toward the most cost-effective care.

What is TrumpRx?

Launched this month, the service is a federal direct-to-consumer platform designed to offer “Most-Favored-Nation,” or “MFN” pricing on select high-cost, brand-name drugs. The platform currently features 43 medications* from manufacturers like Pfizer, Eli Lilly, and Novo Nordisk. The platform notably includes highly sought-after GLP-1s, fertility treatments, and insulin.

While the site itself does not sell medications directly to consumers, it does provide digital and printable coupons that allow patients to access discounted cash prices directly from the manufacturer or at local pharmacies. This system is incredibly similar to other prescription discount platforms like GoodRx; this is intentional, as GoodRx is an integrated pricing partner for the platform, with the same discounted prices for the same drugs offered through both websites. TrumpRx also integrates with direct-to-consumer channels (like LillyDirect and NovoCare).

Key Takeaways for Plan Sponsors

For employers, the introduction of this platform creates both opportunities and challenges for plan design:

The Cash-Pay Distinction: TrumpRx is designed for cash-paying patients. Purchases made through the platform generally do not count toward a member’s insurance deductible or out-of-pocket maximum, an important nuance employees need to understand.

GLP-1 and Specialty Access: For plans that do not currently cover weight-loss or fertility medications, this platform may offer a safety net for employees to access these treatments at a significant discount without impacting the plan’s claims experience.

Generic Alternatives: While the service focuses on brand-name discounts, many of the featured drugs still have lower-cost generic versions available through traditional channels or platforms like Cost Plus Drugs.

Strategy and Guidance

In an ever-evolving benefits market, education is your best competitive advantage. At Bryson, we are always helping our clients analyze how any changes, including these new external pricing tools, impact their current and future strategies.

Bryson Insight:

Before an employee uses a coupon, they should always check their plan co-pay first. In many cases, the negotiated rate within an employer-sponsored plan remains the more financially sound choice, particularly when factoring in the progress toward meeting deductibles. Additionally, cash-pay scripts bypass PBMs and could have a potential impact on your plan’s rebate flow and utilization reporting.

There is also a broader plan-level consideration for self-funded employers. When members fill prescriptions outside the insurance system, those transactions bypass the PBM entirely. Rebate flow can be affected: manufacturer rebates are typically tied to plan utilization of specific drugs, and cash-pay scripts for those same drugs do not generate rebate credit. For plans with robust GLP-1 or specialty drug rebate arrangements, meaningful member migration to TrumpRx could quietly erode that revenue stream. Additionally, those transactions are invisible to utilization reporting. If employees are accessing GLP-1s, fertility medications, or other high-cost therapies through TrumpRx, claims data will not reflect it, creating blind spots in trend analysis, stop-loss exposure assessment, and formulary strategy.

As TrumpRx gains awareness among employees, Bryson will be helping clients evaluate whether, and to what extent, these cash-pay channels are influencing their plan’s cost and rebate picture

Looking Ahead

The current Administration has indicated that additional manufacturers will be added to the platform throughout 2026. Meanwhile, the recently signed Consolidated Appropriations Act of 2026 (CAA 2026) introduces sweeping federal PBM reforms. The law mandates 100% rebate pass-through to plan sponsors, requires detailed semiannual PBM reporting on drug spending and fees, and extends compensation disclosure requirements beyond PBMs to virtually all group health plan service providers, including TPAs and stop-loss carriers. Most provisions take effect in 2028–2029, but plan fiduciaries should begin reviewing their PBM contracts now.

At Bryson, we treat your business as if it were our own. We will continue to monitor these federal shifts to ensure your benefits package remains a high-value tool for retention and wellness.

* – The figure of 43 medications provided is accurate at the time of writing this article. This number is subject to change.